Core Viewpoint - The actual controller of Kangtai Medical, Hu Kun, has reduced his shareholding in the company, which has raised concerns about potential impacts on governance and control, although the company asserts that there will be no change in control or governance structure [1][3]. Shareholding Changes - Hu Kun reduced his shareholding by a total of 7,377,869 shares, representing 1.84% of the company's total share capital, from 188,189,252 shares (46.84%) to 180,811,383 shares (45.00%) [2][3]. - The reduction occurred between May 30, 2025, and June 6, 2025, through both centralized bidding and block trading methods [2][4]. Financial Performance - For the first quarter of 2025, Kangtai Medical reported a revenue of 112 million yuan, a year-on-year increase of 12.77%, and a net profit attributable to shareholders of 16.44 million yuan, up 277.67% compared to the previous year [12][13]. - The company also reported a significant increase in net profit after deducting non-recurring gains and losses, which rose by 515.19% [13]. Market Performance - As of June 11, 2025, Kangtai Medical's stock closed at 14.34 yuan, with a trading volume of 25,000 hands and a total market capitalization of 5.762 billion yuan [12].